Your browser doesn't support javascript.
loading
DNA glycosylase Neil3 regulates vascular smooth muscle cell biology during atherosclerosis development.
Quiles-Jiménez, Ana; Gregersen, Ida; Segers, Filip M; Skarpengland, Tonje; Kroustallaki, Penelope; Yang, Kuan; Kong, Xiang Yi; Lauritzen, Knut H; Olsen, Maria B; Karlsen, Tom Rune; Nyman, Tuula A; Sagen, Ellen L; Bjerkeli, Vigdis; Suganthan, Rajikala; Nygård, Ståle; Scheffler, Katja; Prins, Jurriën; Van der Veer, Eric; Øgaard, Jonas Ds; Fløisand, Yngvar; Jørgensen, Helle F; Holven, Kirsten B; Biessen, Erik A; Nilsen, Hilde; Dahl, Tuva B; Holm, Sverre; Bennett, Martin R; Aukrust, Pål; Bjørås, Magnar; Halvorsen, Bente.
Afiliação
  • Quiles-Jiménez A; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Gregersen I; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Segers FM; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Department of Pharmacology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
  • Skarpengland T; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
  • Kroustallaki P; Department of Clinical Molecular Biology, University of Oslo, Akershus University Hospital, Lørenskog, Norway.
  • Yang K; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Kong XY; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Lauritzen KH; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
  • Olsen MB; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
  • Karlsen TR; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Nyman TA; Department of Immunology, Institute of Clinical Medicine, University of Oslo, Oslo University Hospital Rikshospitalet, Oslo, Norway.
  • Sagen EL; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
  • Bjerkeli V; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
  • Suganthan R; Department of Microbiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
  • Nygård S; Bioinformatics Core Facility, Institute for Medical Informatics, Oslo University Hospital, Oslo, Norway.
  • Scheffler K; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
  • Prins J; Einthoven Laboratory of Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands; Department of Internal Medicine, Nephrology, Leiden University Medical Center, Leiden, the Netherlands.
  • Van der Veer E; Einthoven Laboratory of Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands; Department of Internal Medicine, Nephrology, Leiden University Medical Center, Leiden, the Netherlands.
  • Øgaard JD; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
  • Fløisand Y; Department of Hematology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
  • Jørgensen HF; Division of Cardiovascular Medicine, Department of Medicine, University of Cambridge, Addenbrooke's Centre for Clinical Investigation, Addenbrooke's Hospital, Cambridge, United Kingdom.
  • Holven KB; Norwegian National Advisory Unit on Familial Hypercholesterolemia, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway; Faculty of Medicine, Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
  • Biessen EA; Department of Pathology, University of Maastricht, Maastricht, the Netherlands.
  • Nilsen H; Department of Clinical Molecular Biology, University of Oslo, Akershus University Hospital, Lørenskog, Norway.
  • Dahl TB; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
  • Holm S; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
  • Bennett MR; Division of Cardiovascular Medicine, Department of Medicine, University of Cambridge, Addenbrooke's Centre for Clinical Investigation, Addenbrooke's Hospital, Cambridge, United Kingdom.
  • Aukrust P; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway; Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway.
  • Bjørås M; Department of Microbiology, Oslo University Hospital Rikshospitalet, Oslo, Norway; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
  • Halvorsen B; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway. Electronic address: Bente.Halvorsen@rr-research.no.
Atherosclerosis ; 324: 123-132, 2021 05.
Article em En | MEDLINE | ID: mdl-33714552
BACKGROUND AND AIMS: Atherogenesis involves a complex interaction between immune cells and lipids, processes greatly influenced by the vascular smooth muscle cell (VSMC) phenotype. The DNA glycosylase NEIL3 has previously been shown to have a role in atherogenesis, though whether this is due to its ability to repair DNA damage or to other non-canonical functions is not yet clear. Hereby, we investigate the role of NEIL3 in atherogenesis, specifically in VSMC phenotypic modulation, which is critical in plaque formation and stability. METHODS: Chow diet-fed atherosclerosis-prone Apoe-/- mice deficient in Neil3, and NEIL3-abrogated human primary aortic VSMCs were characterized by qPCR, and immunohistochemical and enzymatic-based assays; moreover, single-cell RNA sequencing, mRNA sequencing, and proteomics were used to map the molecular effects of Neil3/NEIL3 deficiency in the aortic VSMC phenotype. Furthermore, BrdU-based proliferation assays and Western blot were performed to elucidate the involvement of the Akt signaling pathway in the transdifferentiation of aortic VSMCs lacking Neil3/NEIL3. RESULTS: We show that Neil3 deficiency increases atherosclerotic plaque development without affecting systemic lipids. This observation was associated with a shift in VSMC phenotype towards a proliferating, lipid-accumulating and secretory macrophage-like cell phenotype, without changes in DNA damage. VSMC transdifferentiation in Neil3-deficient mice encompassed increased activity of the Akt signaling pathway, supported by cell experiments showing Akt-dependent proliferation in NEIL3-abrogated human primary aortic VSMCs. CONCLUSIONS: Our findings show that Neil3 deficiency promotes atherosclerosis development through non-canonical mechanisms affecting VSMC phenotype involving activation of the Akt signaling pathway.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Miócitos de Músculo Liso / DNA Glicosilases / Aterosclerose / Placa Aterosclerótica Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Miócitos de Músculo Liso / DNA Glicosilases / Aterosclerose / Placa Aterosclerótica Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article